Application of artificial intelligence for preoperative diagnostic and prognostic prediction in epithelial ovarian cancer based on blood biomarkers

…, N Yanaihara, T Ishikawa, K Koseki, Y Iida… - Clinical cancer …, 2019 - AACR
Purpose: We aimed to develop an ovarian cancer–specific predictive framework for clinical
stage, histotype, residual tumor burden, and prognosis using machine learning methods …

[HTML][HTML] Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

…, AM Meynert, T Rye, C Bartos, Y Iida… - Nature …, 2020 - nature.com
Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinical and molecular
heterogeneity. Here, we report whole exome sequencing of 112 EnOC cases following …

Clear cell carcinoma of the ovary: a clinical and molecular perspective

Y Iida, A Okamoto, RL Hollis, C Gourley… - International Journal of …, 2021 - ijgc.bmj.com
Clear cell carcinoma of the ovary has distinct biology and clinical behavior. There are significant
geographical and racial differences in the incidence of clear cell carcinoma compared …

Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma

Y Iida, K Aoki, T Asakura, K Ueda… - International …, 2012 - spandidos-publications.com
Ovarian clear cell carcinoma (OCCC) has several significant characteristics based on
molecular features that are distinct from those of ovarian high-grade serous carcinoma. Cellular …

Analysis of prognostic factors for patients with leiomyoma treated with uterine arterial embolization

S Isonishi, RL Coleman, M Hirama, Y Iida… - American journal of …, 2008 - Elsevier
OBJECTIVE: The objective of the study was to describe a clinically useful factors index
predicting long-term efficacy of uterine artery embolization (UAE). STUDY DESIGN: Newly …

Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification

…, WG McCluggage, ARW Williams, C Bartos, Y Iida… - Clinical Cancer …, 2022 - AACR
Purpose: High-grade serous ovarian carcinoma (HGSOC) is the most common ovarian
cancer type; most patients experience disease recurrence that accumulates chemoresistance, …

[HTML][HTML] Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma

…, H Matsuzawa, M Miyake, M Takenaka, Y Iida… - Scientific Reports, 2021 - nature.com
Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian cancer (EOC) that is
associated with elevated interleukin-6 (IL-6) expression, resistance to chemotherapy, and …

[HTML][HTML] Cytokine gene expression signature in ovarian clear cell carcinoma

…, M Saito, C Nagata, Y Iida… - International …, 2012 - spandidos-publications.com
Cytokine expression in a tumor microenvironment can impact both host defense against the
tumor and tumor cell survival. In this study, we sought to clarify whether the cytokine gene …

[HTML][HTML] PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma

…, K Tachibana, M Saito, A Kawabata, Y Iida… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Ovarian clear cell carcinoma (OCCC) exhibits distinct phenotypes, such as resistance to
chemotherapy, poor prognosis and an association with endometriosis. Biomarkers and imaging …

[HTML][HTML] Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma

RL Hollis, B Stanley, Y Iida, J Thomson… - Gynecologic …, 2019 - Elsevier
Background Numerous studies have investigated the association between hormone receptor
expression and clinical outcome in ovarian carcinoma (OC); however, these have largely …